Publications
Link to CV: here

First Author or Corresponding Author | Refereed
* = equal contribution
# = corresponding author

1. Chow RD*, Guzman CD*, Wang G*, Schmidt F*, Youngblood MW, Ye L, Errami Y, Dong MB, Martinez MA, Zhang S, Renauer P, Bilguvar K, Gunel M, Sharp PA, Zhang F, Platt RJ, Chen S. AAV-mediated direct in vivo CRISPR screen identifies functional suppressors in glioblastoma. Nature Neuroscience. 2017 Aug 14.

2. Wang G*, Chow RD*, Ye L, Guzman CD, Dai X, Dong MB, Zhang F, Sharp PA, Platt RJ, Chen S. Mapping a functional cancer genome atlas of tumor suppressors in mouse liver using AAV-CRISPR mediated direct in vivo screening. Science Advances. 2018 Feb 28.

3. Tata PR*, Chow RD*, Saladi SV, Tata A, Konkimalla A, Bara A, Montoro D, Hariri LP, Shih AR, Mino-Kenudson M, Mou H, Kimura S, Ellisen L, Rajagopal J. Developmental history provides a roadmap for the emergence of tumor plasticity. Developmental Cell. 2018 Mar 26

4. Chow RD, Chen S. Cancer CRISPR screens in vivo. Trends in Cancer. 2018 Mar 29.

5. Chow RD, Kim HR, Chen S. Programmable sequential mutagenesis by inducible Cpf1 crRNA array inversion. Nature Communications. 2018 May 15.

6. Chow RD, Chen S. Sno-derived RNAs are prevalent molecular markers of cancer immunity. Oncogene. 2018 Aug 2.

7. Codina A*, Renauer PA*, Wang G*, Chow RD*, Park JJ, Ye H, Zhang K, Dong M, Gassaway B, Ye L, Errami Y, Shen L, Chang A, Jain D, Herbst RS, Bosenberg M, Rinehart J, Fan R, Chen S. Convergent identification and interrogation of tumor-intrinsic factors that modulate cancer immunity in vivo. Cell Systems. 2019 Feb 27.

8. Chow RD*, Wang G*, Ye L*, Codina A, Kim HR, Shen L, Dong MB, Errami Y, Chen S. In vivo profiling of metastatic double knockouts through CRISPR-Cpf1 screens. Nature Methods. 2019 Apr 9.

9. Dong MB*, Wang G*, Chow RD*, Ye L*, Zhu L, Dai X, Park JJ, Kim HR, Errami Y, Guzman Cd, Zhou X, Chen K, Renauer PA, Du Y, Shen J, Lam S, Zhou J, Lannin DR, Herbst RS, Chen S. Systematic immunotherapy target discovery using genome-scale in vivo CRISPR screens in CD8 T cells. Cell. 2019 Aug 22.

10. Wang G*, Chow RD*, Bai Z, Zhu L, Errami Y, Dai X, Dong MB, Ye L, Zhang X, Renauer PA, Park JJ, Shen L, Ye H, Fuchs CS, Chen S. Multiplexed activation of endogenous genes by CRISPRa elicits potent antitumor immunity. Nature Immunology. 2019 Oct 14.

11. Wang G*, Chow RD*, Zhu L*, Bai Z*, Ye L, Zhang F, Renauer PA, Dong MB, Dai X, Zhang X, Du Y, Cheng Y, Niu L, Chu Z, Kim K, Liao C, Clark P, Errami Y, Chen S. CRISPR-GEMM pooled mutagenic screening identifies KMT2D as a major modulator of immune checkpoint blockade. Cancer Discovery. 2020 Sep 4.

12. Chow RD*, Chen JS*, Shen J, Chen S. A web tool for the design of prime-editing guide RNAs. Nature Biomedical Engineering. 2020 Sep 28.

13. Chow RD, Majety M, Chen S. The aging transcriptome and cellular landscape of the human lung in relation to SARS-CoV-2. Nature Communications. 2021 Jan 4.

14. Chow RD. On the absence of sound. Journal of Clinical Oncology. 2021 Sep 2.

15. Alspach E*, Chow RD*, Demehri S*, Guerriero JL*, Gujar S*, Hacohen N*, Hartmann FJ*, Helmink B*, Hudson WH*, Ho WJ*, Ma L*, Maier BB*, Maltez VI*, Miller BC*, Moran AE*, Parry E*, Pillai PS*, Rafiq S*, Reina-Campos M*, Rosato PC*, Rudqvist N*, Ruhland MK*, Sagiv-Barfi I*, Sahu AD*, Samstein RM*, Schurch CM*, Sen DR*, Thommen DS*, Wolf Y*, Zappasodi R*. Supporting the next generation of scientists to lead cancer immunology research. Cancer Immunology Research. 2021 Sep 20.

16. Chow RD, Bradley EH, Gross CP. Comparison of Cancer-related Spending and Mortality in the US vs 21 High-Income Countries. JAMA Health Forum. 2022 May 27.

17. Song J*, Chow RD*, Pena-Hernandez M*, Zhang L*, Loeb SA, So E, Liang OD, Wilen CB, Lee S. LRRC15 inhibits SARS-CoV-2 cellular entry in trans. PLOS Biology. 2022 Oct 13.

18. Chow RD*#, Michaels T*, Bellone S, Hartwich TMP, Bonazzoli E, Iwasaki A, Song E#, Santin AD#. Distinct mechanisms of mismatch repair deficiency delineate two modes of response to PD-1 immunotherapy in endometrial carcinoma. Cancer Discovery. 2022 Oct 27.

19. Song E, Chow RD#. Mutations in IFN-γ signaling genes sensitize tumors to immune checkpoint blockade. Cancer Cell. 2023 Mar 16.

20. Chow RD, Long JB, Hassan S, Wheeler SB, Spees LP, Leapman MS, Hurwitz ME, McManus HD, Gross CP, Dinan MA. Disparities in immune and targeted therapy utilization for older US patients with metastatic renal cell carcinoma. JNCI Cancer Spectrum. 2023 May 18

21. Chow RD#, Nathanson KL, Parikh RB. Phenotypic evaluation of deep learning models for classifying germline variant pathogenicity. npj Precision Oncology. 2024 Oct 19.

22. Zhang F*, Chow RD*, He E, Dong C, Xin S, Mirza D, Feng Y, Tian X, Verma N, Majety M, Zhang Y, Wang G, Chen S. Multiplexed inhibition of immunosuppressive genes with Cas13d for combinatorial cancer immunotherapy. Nature Biotechnology. 2025 Jan 16.

23. Chow RD*, Velu P*, Deihimi S, Belman J, Youn A, Shah N, Luger SM, Carroll MP, Morrissette J, Bowman RL. Persistent post-remission clonal hematopoiesis shapes the relapse trajectories of acute myeloid leukemia. Blood Advances. 2025 Feb 12.

24. Chow RD#, Mamtani R. Assessment of synergistic vs independent drug activity for enfortumab vedotin and pembrolizumab in untreated advanced urothelial carcinoma. Urologic Oncology. 2025 Aug 1. 

25. Chow RD#, Mamtani R. Association between early on-treatment weight loss with enfortumab vedotin plus pembrolizumab and survival in advanced urothelial carcinoma. Clinical Genitourinary Cancer. 2025 Aug 17.

26. Litt HK, Mamtani R, Chow RD#. Outcomes of enfortumab vedotin plus pembrolizumab in patients with advanced urothelial cancer and severe renal dysfunction. Urologic Oncology. 2025 Nov 13.

27. Chow RD#, Sedhom R, Mamtani R. Reduced-Dose Enfortumab Vedotin, Treatment Continuity, and Survival in Urothelial Cancer. JAMA Oncology. 2025 Nov 13.
    
    

Co-Author | Refereed

1. Pardo-Saganta A*, Tata PR*, Law BM, Saez B, Chow RD, Prabhu M, Gridley T, Rajagopal J. Parent stem cells can serve as niches for their daughter cells. Nature. 2015 Jul 30.

2. Tata A, Kobayashi Y, Chow RD, Tran J, Desai A, Massri AJ, McCord TJ, Gunn MD, Tata PR. Myoepithelial cells of submucosal glands can function as reserve stem cells to regenerate airways after injury. Cell Stem Cell. 2018 Apr 7.

3. Fourati S, Talla A, Mahmoudian M, Burkhart JG, Klén R, Henao R, Yu T, Aydın Z, Yeung KY, Ahsen ME, Almugbel R, Jahandideh S, Liang X, Nordling TEM, Shiga M, Stanescu A, Vogel; Respiratory Viral DREAM Challenge Consortium, Pandey G, Chiu C, McClain MT, Woods CW, Ginsburg GS, Elo LL, Tsalik EL, Mangravite LM, Sieberts SK. A crowdsourced analysis to identify ab initio molecular signatures predictive of susceptibility to viral infection. Nature Communications. 2018 Oct 24.

4. Ye L*, Park JJ*, Dong MB*, Yang Q, Chow RD, Peng L, Du Y, Guo J, Dai X, Wang G, Errami Y, Chen S. In vivo CRISPR screening in CD8 T cells with AAV-Sleeping Beauty hybrid vectors identifies membrane targets for improving immunotherapy for glioblastoma. Nature Biotechnology. 2019 Sep 23.

5. Chen JS, Alfajaro MM, Chow RD, Wei J, Filler RB, Eisenbarth SC, Wilen CB. Non-steroidal anti-inflammatory drugs dampen the cytokine and antibody response to SARS-CoV-2 infection. Journal of Virology. 2021 Jan 13.

6. Ravindra NG*, Alfajaro MM*, Gasque V*, Huston NC, Wan H, Szigeti-Buck K, Yasumoto Y, Greaney AM, Habet V, Chow RD, Chen JS, Wei J, Filler RB, Wang B, Wang G, Niklason LE, Montgomery RR, Eisenbarth SC, Chen S, Williams A, Iwasaki A, Horvath TL, Foxman EF, Pierce RW, Pyle AM, van Dijk D, Wilen CB. Single-cell longitudinal analysis of SARS-CoV-2 infection in human airway epithelium identifies target cells, alterations in gene expression, and cell state changes. PLoS Biology. 2021 Mar 17.

7. Song E, Bartley CM, Chow RD, Ngo TT, Jiang R, Zamecnik CR, Dandekar R, Loudermilk R, Dai Y, Liu F, Sunshine S, Liu J, Wu W, Hawes IA, Alvarenga BD, Huynh T, McAlpine L, Rahman N, Geng B, Chiarella J, Israelow B, Vogels CBF, Grubaugh ND, Casanovas-Massana A, Phinney BS, Salemi M, Alexander JR, Gallego JA, Lencz T, Walsh H, Wapniarski AE, Mohanty S, Lucas C, Klein J, Mao T, Oh J, Ring A, Spudich S, Ko AI, Kleinstein SH, Pak J, DeRisi JL, Iwasaki A, Pleasure SJ, Wilson MR, Farhadian SF. Divergent and self-reactive immune responses in the CNS of COVID-19 patients with neurological symptoms. Cell Reports Medicine. 2021 May 3.

8. Tata A, Chow RD, Tata PR. Epithelial cell plasticity: breaking boundaries and changing landscapes. EMBO Reports. 2021 June 6.

9. Chen JS, Chow RD, Song E, Mao T, Isarelow B, Kamath K, Bozekowski J, Haynes WA, Filler RB, Menasche BL, Wei J, Alfajaro MM, Song W, Peng L, Carter L, Weinstein JS, Gowthaman U, Chen S, Craft J, Shon JC, Iwasaki A, Wilen CB, Eisenbarth SC. High-affinity, neutralizing antibodies to SARS-CoV-2 can be made without T follicular helper cells. Science Immunology. 2021 Dec 16.

10. Ye L*, Park JJ*, Peng L*, Yang Q*, Chow RD, Dong MB, Lam SZ, Guo J, Tang E, Zhang Y, Wang G, Dai X, Du Y, Kim HR, Cao H, Errami Y, Clark P, Bersenev A, Montgomery RR, Chen S. A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy. Cell Metabolism. 2022 Mar 12.

11. Peng L*, Hu Y*, Mankowski MC*, Ren P*, Chen RE, Wei J, Zhao M, Li T, Tripler T, Ye L, Chow RD, Fang Z, Wu C, Dong MB, Cook M, Wang G, Clark P, Nelson B, Klein D, Sutton R, Diamond MS, Wilen CB, Xiong Y, Chen S. Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617. Nature Communications. 2022 Mar 28.

12. Dai X*, Park JJ*, Du Y*, Na Z*, Lam SZ*, Chow RD, Renauer PA, Gu J, Xin S, Chu Z, Liao C, Clark P, Zhao H, Slavoff S, Chen S. Massively parallel knock-in engineering of human T cells. Nature Biotechnology. 2023 Jan 26.

13. Chen JS, Murphy MJ, Singh K, Wang A, Chow RD, Kim SR, Cohen JM, Ko CJ, Damsky W. IL17A mRNA staining distinguishes palmoplantar psoriasis from hyperkeratotic palmoplantar eczema in diagnostic skin biopsies. JID Innovations. 2023 Feb 10.

14. Spadaro JZ, Chow R, Sinard JH, Watsky K, Habib L. Chronic lymphocytic leukemia presenting as bilateral periorbital edema treated with low-dose radiation therapy. Ophthalmic Plast Reconstr Surg. 2023 Feb 28.

15. Strine MS, Cai WL, Wei J, Alfajaro MM, Filler RB, Biering SB, Samik S, Patil A, Cervantes KS, Collings CK, Chow RD, DeWeirdt PC, Hanna RE, Schofield K, Hulme C, Konermann S, Doench JG, Hsu PD, Kadoch C, Yan Q, Wilen CB. DYRK1A promotes viral entry of highly pathogenic human coronaviruses in a kinase independent manner. PLOS Biology. 2023 June 13.

16. Zhou X*, Cao H*, Fang S, Chow RD, Tang K, Majety M, Bai M, Dong MB, Renauer PA, Shang X, Suzuki K, Levchenko A, Chen S. CTLA-4 tail fusion enhances CAR-T anti-tumor immunity. Nature Immunology. 2023 July 27.

17. Peng L*, Renauer PA*, Sferruzza G, Yang L, Zou Y, Fang Z, Park JJ, Chow RD, Zhang Y, Lin Q, Bai M, Sanchez A, Zhang Y, Lam SZ, Ye L, Chen S. In vivo AAV-SB-CRISPR screens of tumor-infiltrating primary NK cells identify genetic checkpoints of CAR-NK therapy. Nature Biotechnology. 2024 June 25.

18. Tang K*, Zhou L*, Tian X, Fang SY, Vandenbulcke E, Du A, Shen J, Cao H, Zhou J, Chen K, Kim HR, Luo Z, Xin S, Lin SH, Park D, Yang L, Zhang Y, Suzuki K, Majety M, Ling X, Lam SZ, Chow RD, Ren P, Tao B, Li K, Codina A, Dai X, Xin B, Bai S, Nottoli T, Levchenko A, Booth CJ, Liu C, Fan R, Dong MB, Zhou X, Chen S. Cas12a-knock-in mice for multiplexed genome editing, disease modelling and immune-cell engineering. Nature Biomedical Engineering. 2025 Mar 20.

Letters and Editorials | Non-refereed

1. Segal L, Chow RD, Kumar B, Nguyen J, Yu KH, Chen J, Polat EO, Porter KE, Kelly-Irving M, Bimpe I, Winter KA, Zeng R, Ahmed M, Saalman DR, James JI, Kosinski M, White ER, Oda FS, Bretscher H, Hamel P, Negi S, Jawaid A. Promoting human rights through science.  Science. 2017 Oct 6. 

2. Olmeta-Schult F, Segal LM, Tyner S, Moon TA, Chow RD, Chakrabarty P, Pacesa M, Podgornaia AI, Chen J, Singh B, Cao B, Sidhu RRS, Tan BWQ, Sood P, Parker S, Scult MA, Van Haute D, Konstantinides N, Schwendimann BA, Srivastava S, Fiorenza R, Dutton-Regester K, Hale R, Polat EO, Lau E, Mayer AL, White ER. NextGen VOICES: Research resolutions. Science. 2018 Jan 5.

Patents

1. US20200010903A1: AAV-Mediated Direct In vivo CRISPR Screen in Glioblastoma

2. WO2018236840A9: Compositions and methods for multiplexed genome editing and screening

3. WO2020037142A1: Compositions and methods for high-throughput activation screening to boost t cell effector function

4. WO2020028533A1: Compositions and methods for identification of membrane targets for enhancement of t cell activity against cancer

5. WO2021108050A3: Compositions and methods comprising viral vector systems for multiplexed activation of endogenous genes as immunotherapy and viral-based immune-gene therapy

6. US20210113674A1: Compositions and methods for multiplexed tumor vaccination with endogenous gene activation

7. US20200017917A1: Mapping a Functional Cancer Genome Atlas of Tumor Suppressors Using AAV-CRISPR Mediated Direct In Vivo Screening